Johnson & Johnson's Future Sales Growth Driven by New Products and Neuroscience Drugs

Johnson & Johnson MedTech has outlined its plans for growth, setting long-term financial targets and emphasizing its position as a leader in healthcare innovation. The company expects at least 3% sales growth in 2025 and a compound annual growth rate of 5%-7% from 2025 to 2030. Johnson & Johnson MedTech aims to achieve this growth through a differentiated pipeline and geographic expansion, particularly in the interventional cardiovascular, robotics, and digital spaces. The company also highlighted recent acquisitions and the development of its Ottava surgical robot as key drivers of growth. Johnson & Johnson MedTech's new head, Tim Schmid, emphasized the importance of advancing the company's pipeline, expanding into high-growth markets, and building operational resilience. The company's integration of Abiomed into its portfolio is performing above expectations, and it plans to make its flagship Impella heart pumps smaller, smarter, and more connected. Johnson & Johnson MedTech also provided an update on its Ottava surgical robot, with plans to submit it for FDA approval in the second half of 2024.